All In Biotech

Drug Trial Radar · NCT00280059

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures

Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

660

Actual

Start

Aug 2006

Primary completion

Dec 2009

Study completion Apr 2010

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.

Conditions

  • Epilepsy, Partial

Interventions

  • PregabalinDrug

    dose 150-600 mg/day given BID

  • LamotrigineDrug

    dose 100-500 mg/day given BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Seizure-free Participants (Responders) During Efficacy Assessment PhaseTime frame: Week 5 up to Week 56

Locations

102 sites in 29 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Bruges, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Leuven, Belgium

  • Pfizer Investigational Site

    Plovdiv, Bulgaria

  • Pfizer Investigational Site

    Sofia, Bulgaria

  • Pfizer Investigational Site

    Sofia, Bulgaria

  • Pfizer Investigational Site

    Sofia, Bulgaria

  • Pfizer Investigational Site

    Varna, Bulgaria

  • Pfizer Investigational Site

    Cheng Du Si Chaun, China

  • Pfizer Investigational Site

    Chongqing, China

  • Pfizer Investigational Site

    Tianjin, China

  • Pfizer Investigational Site

    Xi’an, Shanxi, China

  • Pfizer Investigational Site

    Bogota, Cundinamarca, Colombia

  • Pfizer Investigational Site

    Cali, Valle del Cauca Department, Colombia

  • Pfizer Investigational Site

    Brno, Czechia

  • Pfizer Investigational Site

    Hradec Králové, Czechia

  • Pfizer Investigational Site

    Ostrava, Czechia

  • Pfizer Investigational Site

    Pelhřimov, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Rychnov nad Kněžnou, Czechia

  • Pfizer Investigational Site

    Zlín, Czechia

  • Pfizer Investigational Site

    Tallinn, Estonia

  • Pfizer Investigational Site

    Tartu, Estonia

  • Pfizer Investigational Site

    Kuopio, Finland

  • Pfizer Investigational Site

    Tampere, Finland

  • Pfizer Investigational Site

    Bordeaux, France

  • Pfizer Investigational Site

    Nancy, France

  • Pfizer Investigational Site

    Strasbourg, France

  • Pfizer Investigational Site

    Berlin, Germany

  • Pfizer Investigational Site

    Bonn, Germany

  • Pfizer Investigational Site

    Essen, Germany

  • Pfizer Investigational Site

    Frankfurt, Germany

  • Pfizer Investigational Site

    Ulm, Germany

  • Pfizer Investigational Site

    Ulm, Germany

  • Pfizer Investigational Site

    Hong Kong, Hong Kong

  • Pfizer Investigational Site

    Kowloon, Hong Kong

  • Pfizer Investigational Site

    Shatin, Hong Kong

  • Pfizer Investigational Site

    Budapest, Hungary

  • Pfizer Investigational Site

    Győr, Hungary

  • Pfizer Investigational Site

    Nyíregyháza, Hungary

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.